European Medicines Agency Says On September 25 European Commission Withdrew Marketing Authorization For Exviera In EU; Withdrawal Of Marketing Authorisation For Exviera Was At Request Of Marketing Authorisation Holder, AbbVie Deutschland GmbH & Co. KG; AbbVie Deutschland GmbH & Co. KG, Notified Commission Of Decision To Discontinue Marketing Of Exviera For Commercial Reasons
Portfolio Pulse from Benzinga Newsdesk
The European Medicines Agency announced that the European Commission has withdrawn the marketing authorization for Exviera in the EU. This decision was made at the request of AbbVie Deutschland GmbH & Co. KG, the marketing authorization holder, due to commercial reasons.
October 01, 2024 | 3:40 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AbbVie requested the withdrawal of Exviera's marketing authorization in the EU due to commercial reasons. This may impact AbbVie's revenue from this product in the EU market.
The withdrawal of Exviera from the EU market suggests that AbbVie may not see sufficient commercial viability for the product in this region. This could lead to a short-term negative impact on revenue from Exviera sales in the EU.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80